ICU MEDICAL INC/DE
Customers
1
0 disclosed
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Latest period
Sep 30, 2012
10-Q filed 2012-10-19
Customers 1
Companies ICUI discloses as major customers, as a share of ICUI revenue. 0 active, 1 lapsed.
| Company | % of ICUI revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| HOSPIRA INC HOSPIRA INC |
Named | — | 3M 2012-09-30 | — | Lapsed Last seen 2012-09-30 |
10-Q 2012-10-19 |
• expansion of our custom products business; expectations regarding revenues from our custom infusion sets, custom critical care and custom oncology products and the importance of these products in the future; potential customer resistance to custom products; our focus on increasing product development, acquisition, sales and marketing efforts to custom products and similar products; new or extended contracts with manufacturers and buying organizations; dependence on a small number of customers; future sales to and revenues from Hospira and the importance of Hospira to our growth and our positioning with respect to new product introductions and market share; growth of our CLAVE products in future years; the outcome of our strategic initiatives; outcome of litigation; competitive and market factors, including continuing development of competing products by other manufacturers; consolidation of the healthcare provider market; our dependence on securing long-term contracts with large healthcare providers and major buying organizations; working capital requirements; liquidity and realizable value of our investment securities; future investment alternatives; our expectations regarding liquidity and capital resources over the next twelve months; future share repurchases; acquisitions of other businesses or product lines, indemnification liabilities and contractual liabilities. • expansion of our custom products business; expectations regarding revenues from our custom infusion sets, custom critical care and custom oncology products and the importance of these products in the future; potential customer resistance to custom products; our focus on increasing product development, acquisition, sales and marketing efforts to custom products and similar products; new or extended contracts with manufacturers and buying organizations; dependence on a small number of customers; future sales to and revenues from Hospira and the importance of Hospira to our growth and our positioning with respect to new | ||||||
Alerts are coming
Get an email when ICUI's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.